IMPEDIMED LTD Aktie

View in Terminal

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, IMPEDIMED LTD Aktie had revenue of €4.3m and net profit of -€7.65m

(EUR)	June 2026	YoY
Revenue	4.3m	-
Gross profit	-3.25m	-
Net profit	-7.65m	-
EBITDA	-4.55m	-

Fundamentals

Metric	Value
Market capitalization	€9.19m
Number of shares	3.66bn
52-week high/low	€0.032 - €0.00188
Dividends	No
Beta	1.07
P/E ratio	-0.34
PEG ratio	0.30
P/B ratio	0.88
P/S ratio	1.00

Company profile

ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.